Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 26:26:444-457.
doi: 10.1016/j.omtn.2021.08.027. eCollection 2021 Dec 3.

miR-320a induces pancreatic β cells dysfunction in diabetes by inhibiting MafF

Affiliations

miR-320a induces pancreatic β cells dysfunction in diabetes by inhibiting MafF

Hengzhi Du et al. Mol Ther Nucleic Acids. .

Abstract

A variety of studies indicate that microRNAs (miRNAs) are involved in diabetes. However, the direct role of miR-320a in the pathophysiology of pancreatic β cells under diabetes mellitus remains unclear. In the current study, islet transplantation and hyperglycemic clamp assays were performed in miR-320a transgenic mice to explore the effects of miR-320a on pancreatic β cells in vivo. Meanwhile, β cell-specific overexpression or inhibition of miR-320a was delivered by adeno-associated virus (AAV8). In vitro, overexpression or downregulation of miR-320a was introduced in cultured rat islet tumor cells (INS1). RNA immunoprecipitation sequencing (RIP-Seq), luciferase reporter assay, and western blotting were performed to identify the target genes. Results showed that miR-320a was increased in the pancreatic β cells from high-fat-diet (HFD)-treated mice. Overexpression of miR-320a could not only deteriorate the HFD-induced pancreatic islet dysfunction, but also initiate pancreatic islet dysfunction spontaneously in vivo. Meanwhile, miR-320a increased the ROS level, inhibited proliferation, and induced apoptosis of cultured β cells in vitro. Finally, we identified that MafF was the target of miR-320a that responsible for the dysfunction of pancreatic β cells. Our data suggested that miR-320a could damage the pancreatic β cells directly and might be a potential therapeutic target of diabetes.

Keywords: MafF; diabetes; miRNA; pancreatic islet; β cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

None
Graphical abstract
Figure 1
Figure 1
miR-320a was increased in HFD damaged pancreatic β cells (A) Body weight was measured every three weeks since the age of 8 weeks and results for the 12 weeks; data are expressed as mean ± SEM, n = 6. ∗p < 0.05, calculated by two-way ANOVA analysis. (B) Blood glucose was measured every three weeks since the age of 8 weeks and results for the 12 weeks; data are expressed as mean ± SEM, n = 6. ∗∗p < 0.01, calculated by two-way ANOVA analysis. (C) Insulin level was measured every three weeks since the age of 8 weeks and results for the 12 weeks; data are expressed as mean ± SEM, n = 5. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (D) Islets were isolated from each time point mice and cultured for 48 h. Then insulin secretion from islets was determined in response to 2.8- or 22-mM glucose; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by two-way ANOVA analysis. (E) Representative images of immunofluorescence staining for miR-320a (red), insulin (green), and Hoechst (blue) in islets from wild-type mice. Scale bar, 25 μm. (F) Relative miR-320a expression in isolated islets measured by real-time PCR; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by one-way ANOVA analysis. (G) and (H) Apoptosis of INS1 were determined by Annexin V/PI flow cytometric analysis; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (I) Relative miR-320a expression in INS1 measured by real-time PCR; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis.
Figure 2
Figure 2
Overexpression of miR-320a aggravated the HFD-induced damages in pancreatic β cells in vivo (A) Pancreatic islets from miR-320a transgenic (TG) or wild-type (WT) mice were isolated and cultured. Insulin secretion was determined in response to 2.8 or 22mM glucose; data are expressed as mean ± SEM, n = 5. ∗p < 0.05, calculated by two-way ANOVA analysis. (B) Model of islet transplantation. (C) Streptozocin (STZ)-induced diabetic WT mice were transplanted with an appropriate amount (100) of WT islets or miR-320a transgenic (TG) mice islets. Blood glucose levels were monitored for 6 weeks, and results expressed as area under the curve; data are expressed as mean ± SEM, n = 5. ∗p < 0.05, calculated by Student’s t test. Diabetic mice receiving WT or TG mice islets were fasted overnight and glucose tolerance tests (1.0 g/kg body weight) were performed at 6 weeks post-transplant. Diabetic mice receiving WT or TG mice islets were fasted overnight and hyperglycemic clamp experiments were performed at 6 weeks post-transplant. Plasma glucose (D) and - GINF (E) were measured during hyperglycemic clamps. Insulin (F) and C-peptide levels (G) before and during the last 20 min of the hyperglycemic clamp and (H) disposition indexes (DI = GINF/insulin x C-peptide) during the last 20 min of hyperglycemic clamp in mice; data are expressed as mean ± SEM, n = 5. ∗p < 0.05, ∗∗p < 0.01, calculated by two-way ANOVA analysis. (I) Representative images of immunofluorescence staining for TUNEL (green), insulin (red), and Hoechst (blue) in transplanted islets from WT-WT or TG-WT mice. Scale bar, 10 μm. Data are expressed as mean ± SEM, n = 3, ∗∗p < 0.01, calculated by Student’s t test. (J) Diabetic mice receiving WT or TG mice islets were fed with high-fat diet for another 6 weeks and blood glucose levels were monitored, and results expressed as area under the curve, data are expressed as mean ± SEM, n = 5. ∗∗p < 0.01, calculated by two-way ANOVA analysis. Diabetic mice receiving WT or TG mice islets were fasted overnight and glucose tolerance tests (1.0 g/kg body weight) were performed at 6 weeks post-transplant. Diabetic mice receiving WT or TG mice islets were fasted overnight and hyperglycemic clamp experiments were performed at 6 weeks post-transplant. Plasma glucose (K) and GINF (L) were measured during hyperglycemic clamps. Insulin (M) and C-peptide levels (N) before and during the last 20 min of the hyperglycemic clamp, data are expressed as mean ± SEM, n = 5. ∗p < 0.05, ∗∗p < 0.01, calculated by two-way ANOVA analysis. (O) Disposition indexes during the last 20 min of hyperglycemic clamp in mice; data are expressed as mean ± SEM, n = 5. ∗p < 0.05, calculated by one-way ANOVA analysis. (P) Representative images of immunofluorescence staining for TUNEL (green), insulin (red), and Hoechst (blue) in transplanted islets from WT-WT+HFD or TG-WT+HFD mice. Scale bar, 10 μm. Data are expressed as mean ± SEM, n = 3, ∗p < 0.05, calculated by Student’s t test.
Figure 3
Figure 3
Overexpression of miR-320a damaged pancreatic β cells in vitro INS1 cells were transfected with miR-320a mimics/inhibitors and then subjected to palmitate (0.3 mmol/L) stimulation. (A) and (B) Effects of miR-320a mimics/inhibitors on proliferation were determined by EdU flow cytometric analysis in cultured INS1 cells; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by one-way ANOVA analysis. (C) and (D) Effects of miR-320a mimics/inhibitors on apoptosis were determined by Annexin V/PI flow cytometric analysis in cultured INS1 cells; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (E) and (F) Effects of miR-320a mimics/inhibitors on the ROS levels were determined by DCFH-DA flow cytometric analysis in cultured INS1 cells; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis.
Figure 4
Figure 4
miR-320a suppressed the function of pancreatic β cells via MafF (A) Heatmap and Volcano plot (B) of the genes in RIP-seq using anti-Ago2 antibody in INS1 cells following miR-320a mimics or miR-con transfection. n = 2. (C) Venn diagram showing the overlap number of candidate target genes of miR-320a identified by Ago2-RIP-seq, which contained the binding sites of miR-320a among rat, mouse, and human species predicted by RNAhybrid. (D) Regulation of miR-320a on 3′-UTR of Ift57, Krt8, Ddrgk1, Cald1, MafF, Mlec, Meltf and Klhl36 in INS1 cells by luciferase reporter assay; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by Student’s t test. (E) Sequence alignment of binding sites between miR-320a and the 3′-UTR of MafF among several species. (F and G) Relative expression of MafF detected by western blot. Data are expressed as mean ± SEM, n = 3, ∗p < 0.05, calculated by one-way ANOVA analysis.
Figure 5
Figure 5
MafF restoration attenuated miR-320a induced pancreatic β cells dysfunction in vivo (A)–(D) Body weight and blood glucose levels were monitored for 7 weeks and results were expressed as area under the curve; data are expressed as mean ± SEM, n = 10. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (E) Pancreatic islets from mice treated with AAV8-insulin vectors under normal diet were isolated and cultured. Insulin secretion was determined in response to 2.8 or 22mM glucose; data are expressed as mean ± SEM, n = 5. ∗p < 0.05, calculated by two-way ANOVA analysis. Plasma glucose (F) and GINF (G) were measured during hyperglycemic clamps. (H) and (I) Insulin and C-peptide levels before and during the last 20 min of the hyperglycemic clamp during the last 20 min of hyperglycemic clamp in mice; data are expressed as mean ± SEM, n = 6. ∗p < 0.05, calculated by two-way ANOVA analysis. (J) Disposition indexes (DI = GINF/insulin x C-peptide) during the last 20 min of hyperglycemic clamp in mice; data are expressed as mean ± SEM, n = 4. ∗p < 0.05, calculated by two-way ANOVA analysis. (K) and (L) Representative images of immunofluorescence staining for TUNEL (green), insulin (red), and Hoechst (blue) in islets from HFD mice treated with pancreatic β cells specific insulin vectors (AAV8-insulin). Scale bar, 20 μm. Data are expressed as mean ± SEM, n = 5, ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis.
Figure 6
Figure 6
MiR-320a damaged pancreatic β cells via inhibiting MafF/Nrf2 complex (A) Relative MafF protein levels in HFD mice detected by western blot; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (B) Relative MafF protein levels detected INS1 cells treated with palmitate by western blot; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (C) Relative MafF protein levels detected by western blot; data are expressed as mean ± SEM, n = 4. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (D) Proliferation was determined by immunohistochemical staining for EdU (green) and Hoechst (blue) in cultured INS1 cells; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, ∗∗p < 0.01, calculated by one-way ANOVA analysis. (E) Apoptosis was determined by Annexin V/PI flow cytometric analysis in cultured INS1 cells; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by one-way ANOVA analysis. (F) The ROS levels were determined by DCFH-DA flow cytometric analysis in cultured INS1 cells; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by one-way ANOVA analysis. (G) Relative Nrf2 protein level detected by western blot. (H) Relative mRNA levels of NQO1, HO-1 measured by real-time PCR under HFD conditions; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by one-way ANOVA analysis. (I) Relative mRNA levels of NQO1, HO-1 measured by real-time PCR under palmitate conditions; data are expressed as mean ± SEM, n = 3. ∗p < 0.05, calculated by one-way ANOVA analysis (J) Schematic representation of the role of miR-320a in β cells dysfunction. Overexpression of miR-320a enhanced the oxidative stress of β cells via inhibiting the MafF/Nrf2 signal pathway to increase the ROS level, inhibit the proliferation and induce the apoptosis, thus leading to the reduction of insulin release, which finally impaired the secretion of insulin.

Similar articles

Cited by

References

    1. Dennis J.M., Shields B.M., Henley W.E., Jones A.G., Hattersley A.T. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019;7:442–451. - PMC - PubMed
    1. Tesfaye B., Alebel A., Gebrie A., Zegeye A., Tesema Leshargie C., Ferede A., Abera H., Alam K. Diabetes mellitus and its association with hypertension in Ethiopia: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2019;156:107838. - PubMed
    1. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806. - PubMed
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–S90. - PubMed
    1. Vantyghem M.C., de Koning E.J.P., Pattou F., Rickels M.R. Advances in β-cell replacement therapy for the treatment of type 1 diabetes. Lancet. 2019;394:1274–1285. - PMC - PubMed

LinkOut - more resources